Royalty Pharma PLC RPRX
We take great care to ensure that the data presented and summarized in this overview for Royalty Pharma plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RPRX
View all-
Morgan Stanley New York, NY41MShares$1.47 Billion0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA36.7MShares$1.32 Billion0.02% of portfolio
-
Black Rock Inc. New York, NY23MShares$826 Million0.01% of portfolio
-
Baillie Gifford & CO13.4MShares$481 Million0.38% of portfolio
-
Swedbank Ab Stockholm, V712.2MShares$436 Million0.51% of portfolio
-
Viking Global Investors LP10.6MShares$379 Million1.1% of portfolio
-
State Street Corp Boston, MA9.52MShares$341 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA8MShares$287 Million0.02% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA6.25MShares$224 Million0.38% of portfolio
-
Caledonia (Private) Investments Pty LTD Sydney Nsw, C35.11MShares$183 Million3.99% of portfolio
Latest Institutional Activity in RPRX
Top Purchases
Top Sells
About RPRX
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Insider Transactions at RPRX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 30
2025
|
Henry A Fernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,064
+1.6%
|
$37,240
$35.24 P/Share
|
Jun 30
2025
|
Bonnie L Bassler Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,064
+1.47%
|
$37,240
$35.24 P/Share
|
May 16
2025
|
Legorreta Pablo G. CEO, Chairman of the Board |
BUY
Other acquisition or disposition
|
Direct |
530,348
+37.54%
|
-
|
May 13
2025
|
Catherine M. Engelbert Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,614
+12.96%
|
-
|
May 13
2025
|
David C Hodgson Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,614
+18.6%
|
-
|
May 13
2025
|
Ted W Love Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,614
+12.39%
|
-
|
May 13
2025
|
Gregory Norden Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,614
+8.34%
|
-
|
May 13
2025
|
Bonnie L Bassler Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,614
+9.8%
|
-
|
May 13
2025
|
Vlad Coric Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,614
+41.35%
|
-
|
May 13
2025
|
Errol B Desouza Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,614
+8.56%
|
-
|
May 13
2025
|
Henry A Fernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,614
+10.59%
|
-
|
May 08
2025
|
George W. Lloyd EVP, Investments & CLO |
BUY
Grant, award, or other acquisition
|
Indirect |
48,646
+50.0%
|
-
|
May 08
2025
|
Legorreta Pablo G. CEO, Chairman of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
288,352
+45.02%
|
-
|
May 08
2025
|
Terrance P. Coyne EVP & CFO |
BUY
Grant, award, or other acquisition
|
Indirect |
48,646
+50.0%
|
-
|
May 08
2025
|
Christopher Hite EVP & Vice Chairman |
BUY
Grant, award, or other acquisition
|
Indirect |
48,646
+6.98%
|
-
|
May 08
2025
|
Marshall Urist EVP, Research & Investments |
BUY
Grant, award, or other acquisition
|
Direct |
36,484
+30.5%
|
-
|
Apr 21
2025
|
Vlad Coric Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,184
+50.0%
|
-
|
Mar 31
2025
|
Henry A Fernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,141
+1.97%
|
$36,512
$32.87 P/Share
|
Mar 31
2025
|
Bonnie L Bassler Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,141
+1.79%
|
$36,512
$32.87 P/Share
|
Feb 14
2025
|
Christopher Hite EVP & Vice Chairman |
BUY
Conversion of derivative security
|
Indirect |
300,000
+33.33%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 545K shares |
---|---|
Other acquisition or disposition | 530K shares |
Conversion of derivative security | 300K shares |